Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Trends Pharmacol Sci. 2012 Apr 13;33(5):268–272. doi: 10.1016/j.tips.2012.03.007

Table 1.

Docking hit rates against GPCRs.

Target Hit Rate (actives/tested) New Scaffolds Best Affinity
β2 AR [32] 24% (6/25) 2 9 nM
A2a Aden [36] 41% (23/56) 4 32 nM
A2a Aden [31] 35% (7/20) 2 200 nM
D3 x-ray [31] 20% (5/25) 2 300 nM
D3 homology model [35] 23% (6/26) 2 200 nM
H1 histamine [45] 73% (19/26) 10+ 6 nM